Back to top
more

Aligos Therapeutics (ALGS)

(Delayed Data from NSDQ)

$0.79 USD

0.79
112,534

+0.04 (4.93%)

Updated Apr 22, 2024 11:56 AM ET

After-Market: $0.81 +0.02 (2.92%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Certara, Inc. (CERT) Lags Q4 Earnings Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 1.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aligos Therapeutics, Inc. (ALGS) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -8.16% and 36.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.

Illumina (ILMN) Misses Q4 Earnings Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

by Zacks Equity Research

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.

Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues trump estimates in the first quarter of 2022.

Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio

by Zacks Equity Research

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.

    Molina Healthcare (MOH) to Post Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Molina Healthcare's (MOH) first-quarter results are likely to reflect the benefits of increased membership in the Medicare program.

    Teladoc (TDOC) Eyes Q1 Earnings Beat on Rising US Paid Members

    by Zacks Equity Research

    Teladoc Health's (TDOC) first-quarter 2022 results are likely to reflect improved subscription access fees revenues.

    Ultragenyx (RARE) Begins Dosing in Pivotal Study on Setrusumab

    by Zacks Equity Research

    Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.

    Universal Health (UHS) to Post Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Universal Health Services' (UHS) first-quarter results are likely to reflect the benefits of increased admissions.

    Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal

    by Zacks Equity Research

    Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.

    aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod

    by Zacks Equity Research

    The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.

    Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev

    by Zacks Equity Research

    The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

    Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA

    by Zacks Equity Research

    Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA. Shares down.

    Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision

    by Zacks Equity Research

    The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the delay

    Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Up

    by Zacks Equity Research

    Strong execution across business segments, led by COVID-19 vaccinations and testing, drove Walgreens' (WBA) fiscal second-quarter top line.

    Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

    by Zacks Equity Research

    Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

    All You Need to Know About Aligos Therapeutics, Inc. (ALGS) Rating Upgrade to Buy

    by Zacks Equity Research

    Aligos Therapeutics, Inc. (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Can Aligos Therapeutics, Inc. (ALGS) Climb 91% to Reach the Level Wall Street Analysts Expect?

    by Zacks Equity Research

    The mean of analysts' price targets for Aligos Therapeutics, Inc. (ALGS) points to a 91.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.